SIAG
CLRB icon

Safeguard Investment Advisory Group’s Cellectar Biosciences CLRB Stock Holding History

Safeguard Investment Advisory Group’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3
Closed -$2K – 190
2020
Q4 		$2K Buy
+3
New +$1.38K ﹤0.01% 616

Other funds holding CLRB

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Safeguard Investment Advisory Group's CLRB Position: Q1 2021 in Review

Safeguard Investment Advisory Group sold out of Cellectar Biosciences (CLRB) in Q1 2021, closing a stake of 3 shares — an estimated $2K sold.

Safeguard Investment Advisory Group first reported a position in CLRB in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 44 funds tracked by Wall St. Rank hold CLRB as of Q1 2021.

  • Safeguard Investment Advisory Group reported no remaining Cellectar Biosciences position as of Q1 2021 after selling out during the quarter.
  • Safeguard Investment Advisory Group sold 3 Cellectar Biosciences shares in Q1 2021, an estimated $2K.
  • Safeguard Investment Advisory Group first reported a position in Cellectar Biosciences in Q4 2020 and held it in 1 quarter.
  • Safeguard Investment Advisory Group's Cellectar Biosciences position peaked at $2K in Q4 2020.
  • 44 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2021.

Based on Safeguard Investment Advisory Group's 13F filing for Q1 2021, filed 10 May 2021.